Document Detail


Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction.
MedLine Citation:
PMID:  16401674     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIMS: Early statin treatment has beneficial effects on prognosis after acute coronary syndrome. The no-reflow phenomenon determines the prognosis after acute myocardial infarction. We investigated the effects of statin treatment before admission on the development of the no-reflow after infarction. METHODS AND RESULTS: We performed intracoronary myocardial contrast echocardiography in 293 consecutive patients with acute myocardial infarction undergoing successful primary percutaneous coronary intervention. There were no significant differences in the incidence of the no-reflow between the patients with and without hypercholesterolaemia. The 33 patients receiving chronic statin treatment before admission had lower incidence of the no-reflow than those without it (9.1 and 34.6%, P=0.003). They also showed better wall motion, smaller left ventricular dimensions, and better ejection fraction at 4.9+/-2.2 months later. Multivariable logistic regression analysis revealed that statin pre-treatment was a significant predictor of the no-reflow along with anterior wall infarction, ejection fraction on admission, and additional ST-elevation after reperfusion, whereas total cholesterol was not. CONCLUSION: Chronic pre-treatment with statins could preserve the microvascular integrity after acute myocardial infarction independent of lipid lowering, leading to better functional recovery.
Authors:
Katsuomi Iwakura; Hiroshi Ito; Shigeo Kawano; Atsushi Okamura; Toshiya Kurotobi; Motoo Date; Koichi Inoue; Kenshi Fujii
Related Documents :
11256844 - Statin therapy: where are we? where do we go next?
8438744 - Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemi...
3698244 - Relationship of angiographically defined coronary artery disease to serum lipoproteins ...
10150224 - Surrogate end-points: the case of trials on coronary atherosclerotic plaque regression.
7963104 - Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase ...
1894864 - Demonstration of myocardial reperfusion injury in humans: results of a pilot study util...
Publication Detail:
Type:  Journal Article     Date:  2006-01-09
Journal Detail:
Title:  European heart journal     Volume:  27     ISSN:  0195-668X     ISO Abbreviation:  Eur. Heart J.     Publication Date:  2006 Mar 
Date Detail:
Created Date:  2006-02-20     Completed Date:  2006-07-24     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  England    
Other Details:
Languages:  eng     Pagination:  534-9     Citation Subset:  IM    
Affiliation:
Division of Cardiology, Sakurabashi Watanabe Hospital, 2-4-32, Umeda, Kita-ku, Osaka 5300001, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Analysis of Variance
Angioplasty, Transluminal, Percutaneous Coronary
Coronary Circulation / drug effects*,  physiology
Echocardiography
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Male
Middle Aged
Myocardial Infarction / physiopathology,  therapy*,  ultrasonography
Myocardial Reperfusion
Regression Analysis
Stents
Stroke Volume
Treatment Outcome
Chemical
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Association between the metabolic syndrome and parental history of premature cardiovascular disease.
Next Document:  Long-term anticoagulant therapy in patients with coronary artery disease.